Tanespimycin (17-AAG) is a cell permeable, less toxic and more stable semi-synthetic analog of geldanamycin. 17-AAG is a potent HSP90 inhibitor displaying a 100-fold higher affinity for tumor cell derived HSP90 over normal cell HSP90. 17-AAG displays anti-angiogenic activity and sensitizes tumor cells to apoptosis in response to such agents as taxol and cisplatin. Tanespimycin (17-AAG) depletes cellular STK38/NDR1 and reduces STK38 kinase activity. Tanespimycin (17-AAG) also downregulates stk38 gene expression.
|Purity||>98% by TLC|
|Quantity||1 mg, 5 mg|
|Molecular Weight||585.7 g/mol|
|Physical State||Lyophilized red to dark red powder|
|Solubility||>50 mg/ml in DMSO; 5 mg/mL in ethanol|
|Storage||-20°C, avoid freeze/thaw cycles|